# AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring

> **NCT07210021** · — · RECRUITING · sponsor: **AccurKardia, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Hyperkalemia
- Chronic Kidney Disease (Stage 3-4)

## Interventions

- **DEVICE:** AK+ Guard™ ECG Application

## Key facts

- **NCT ID:** NCT07210021
- **Lead sponsor:** AccurKardia, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-14
- **Primary completion:** 2025-11
- **Final completion:** 2025-11-28
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07210021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07210021, "AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07210021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*